HTI-501
/ Halozyme
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 07, 2013
Halozyme reports second quarter 2013 financial results
(Halozyme Therapeutics Press Release)
- "Interim results from a Phase 1/2 clinical trial evaluating HTI-501 for use in aesthetic dermatology were available...Results indicate pharmacologic activity at the primary 28 day observation endpoint....The interim results were presented at the 9th Annual World Congress of Cosmetic Dermatology."
Conference • P1/2 data • Fibrosis
1 to 1
Of
1
Go to page
1